Corneal neovascularization: an anti-VEGF therapy review
Jin-Hong Chang, Nitin K Garg, Elisa Lunde, Kyu-Yeon Han, Sandeep Jain, Dimitri T Azar, Jin-Hong Chang, Nitin K Garg, Elisa Lunde, Kyu-Yeon Han, Sandeep Jain, Dimitri T Azar
Abstract
Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors.
Conflict of interest statement
VII. Disclosure
The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. Publication for this article was supported by National Institute of Health (Bethesda, MD) grants EY021886 (JHC), EY10101 (DTA), EY01792 (DTA) and an unrestricted grant from Research to Prevent Blindness, New York, NY.
Copyright © 2012 Elsevier Inc. All rights reserved.
Source: PubMed